We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

119 hedge funds and large institutions have $833M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 33 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,592% more call options, than puts

Call options by funds: $1.61M | Put options by funds: $24K

30% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 33

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

1% less funds holding

Funds holding: 120 → 119 (-1)

12% less capital invested

Capital invested by funds: $951M → $833M (-$118M)

Holders
119
Holders Change
-1
Holders Change %
-0.83%
% of All Funds
1.83%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
19
Increased
43
Reduced
33
Closed
18
Calls
$1.61M
Puts
$24K
Net Calls
+$1.58M
Net Calls Change
-$3.78M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$35.6M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$27M
3
FLAM
First Light Asset Management
Minnesota
+$11M
4
LGM
Logos Global Management
California
+$9.11M
5
Millennium Management
Millennium Management
New York
+$6.88M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$36.9M
2
CS
Candriam SCA
Luxembourg
-$11.9M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.03M
4
Citigroup
Citigroup
New York
-$4.23M
5
OCA
Octagon Capital Advisors
New York
-$4.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$5.21M +$2.9M +151,219 +106%
BBA
27
Baker Bros. Advisors
New York
$5.17M – – –
Charles Schwab
28
Charles Schwab
California
$4.97M +$100K +5,222 +2%
Two Sigma Advisers
29
Two Sigma Advisers
New York
$4.72M +$1.94M +101,000 +61%
HWAM
30
Hennion & Walsh Asset Management
New Jersey
$4.55M -$388K -20,232 -7%
N
31
Nuveen
North Carolina
$4.53M +$1.53M +79,824 +45%
Two Sigma Investments
32
Two Sigma Investments
New York
$4.19M +$544K +28,339 +14%
Goldman Sachs
33
Goldman Sachs
New York
$3.66M -$857K -44,671 -18%
SAM
34
Silvercrest Asset Management
New York
$3.32M – – –
Lord, Abbett & Co
35
Lord, Abbett & Co
New Jersey
$3.29M +$3.84K +200 +0.1%
Deutsche Bank
36
Deutsche Bank
Germany
$2.98M -$153K -7,991 -5%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.28M +$218K +11,387 +10%
DCM
38
DAFNA Capital Management
California
$1.43M +$288K +15,000 +23%
SG Americas Securities
39
SG Americas Securities
New York
$1.34M +$992K +51,692 +216%
Renaissance Technologies
40
Renaissance Technologies
New York
$1.32M +$1.18M +61,400 +462%
Swiss National Bank
41
Swiss National Bank
Switzerland
$1.2M – – –
PAM
42
Panagora Asset Management
Massachusetts
$1.19M +$1.29M +67,066 New
CSS
43
Cubist Systematic Strategies
Connecticut
$1.07M +$411K +21,422 +55%
D.E. Shaw & Co
44
D.E. Shaw & Co
New York
$1.06M +$287K +14,953 +33%
PP
45
PDT Partners
New York
$1.02M +$63.3K +3,300 +6%
Barclays
46
Barclays
United Kingdom
$987K +$451K +23,499 +73%
Invesco
47
Invesco
Georgia
$920K +$52.4K +2,730 +6%
Bank of America
48
Bank of America
North Carolina
$814K +$249K +12,961 +39%
SO
49
STRS Ohio
Ohio
$795K +$226K +11,800 +36%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$764K +$14.5K +758 +2%
1
2
3 4 5

NGM Hedge Fund Activity: Q4 2021 in Review

119 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q4 2021, worth a combined $833M — down 12% from $951M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new NGM positions and 18 closed out — a net gain of 1 holder — while 43 added to existing stakes and 33 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $35.6M. The largest seller was Redmile Group, cutting an estimated $36.9M.

  • 119 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q4 2021, down from 120 in Q3 2021.
  • Funds reported $833M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q4 2021, down 12% quarter-over-quarter.
  • 19 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q4 2021 and 18 closed out, a net change of +1 holder.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Point72 Asset Management, an estimated $35.6M added.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q4 2021 was Redmile Group, an estimated $36.9M sold.

Based on aggregated 13F filings for Q4 2021.